Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onapristone ER in PR+ Gynecologic Cancers
NCT03909152Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2019
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of onapristone extended release in granulosa cell tumor of the ovary (GCT), Low grade serous ovarian cancer (LGSOC), endometrioid endometrial cancer, primary peritoneal cancer (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2019; status: completed.
02
Drugs
onapristone extended release
03
Conditions
granulosa cell tumor of the ovary (GCT)Low grade serous ovarian cancer (LGSOC)endometrioid endometrial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03909152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909152.